#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Hypothalamic Responses to Cocaine and Food Cues in Individuals with Cocaine Dependence Abstract Background Individuals with cocaine addiction are characterized by under-responsiveness to natural reinforcers.
1-1	0-12	Hypothalamic	_
1-2	13-22	Responses	_
1-3	23-25	to	_
1-4	26-33	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-5	34-37	and	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-6	38-42	Food	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-7	43-47	Cues	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-8	48-50	in	_
1-9	51-62	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-10	63-67	with	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-11	68-75	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-12	76-86	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-13	87-95	Abstract	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-14	96-106	Background	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-15	107-118	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-16	119-123	with	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-17	124-131	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-18	132-141	addiction	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-19	142-145	are	_
1-20	146-159	characterized	_
1-21	160-162	by	_
1-22	163-183	under-responsiveness	_
1-23	184-186	to	_
1-24	187-194	natural	_
1-25	195-206	reinforcers	_
1-26	207-208	.	_

Text=As part of the dopaminergic pathways, the hypothalamus supports motivated behaviors.
2-1	209-211	As	_
2-2	212-216	part	_
2-3	217-219	of	_
2-4	220-223	the	_
2-5	224-236	dopaminergic	_
2-6	237-245	pathways	_
2-7	246-247	,	_
2-8	248-251	the	_
2-9	252-264	hypothalamus	_
2-10	265-273	supports	_
2-11	274-283	motivated	_
2-12	284-293	behaviors	_
2-13	294-295	.	_

Text=Rodent studies suggested inter-related roles of the hypothalamus in regulating drug and food intake.
3-1	296-302	Rodent	_
3-2	303-310	studies	_
3-3	311-320	suggested	_
3-4	321-334	inter-related	_
3-5	335-340	roles	_
3-6	341-343	of	_
3-7	344-347	the	_
3-8	348-360	hypothalamus	_
3-9	361-363	in	_
3-10	364-374	regulating	_
3-11	375-379	drug	_
3-12	380-383	and	_
3-13	384-388	food	_
3-14	389-395	intake	_
3-15	396-397	.	_

Text=However, few studies have investigated hypothalamic responses to drugs and food or related cues in humans.
4-1	398-405	However	_
4-2	406-407	,	_
4-3	408-411	few	_
4-4	412-419	studies	_
4-5	420-424	have	_
4-6	425-437	investigated	_
4-7	438-450	hypothalamic	_
4-8	451-460	responses	_
4-9	461-463	to	_
4-10	464-469	drugs	_
4-11	470-473	and	_
4-12	474-478	food	_
4-13	479-481	or	_
4-14	482-489	related	_
4-15	490-494	cues	_
4-16	495-497	in	_
4-17	498-504	humans	_
4-18	505-506	.	_

Text=Methods We examined regional responses in 20 cocaine-dependent and 24 healthy control participants exposed to cocaine/food (cocaine dependent) and food (healthy control) vs neutral cues during functional magnetic resonance imaging.
5-1	507-514	Methods	_
5-2	515-517	We	_
5-3	518-526	examined	_
5-4	527-535	regional	_
5-5	536-545	responses	_
5-6	546-548	in	_
5-7	549-551	20	_
5-8	552-569	cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
5-9	570-573	and	_
5-10	574-576	24	_
5-11	577-584	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-12	585-592	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-13	593-605	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-14	606-613	exposed	_
5-15	614-616	to	_
5-16	617-629	cocaine/food	_
5-17	630-631	(	_
5-18	632-639	cocaine	_
5-19	640-649	dependent	_
5-20	650-651	)	_
5-21	652-655	and	_
5-22	656-660	food	_
5-23	661-662	(	_
5-24	663-670	healthy	_
5-25	671-678	control	_
5-26	679-680	)	_
5-27	681-683	vs	_
5-28	684-691	neutral	_
5-29	692-696	cues	_
5-30	697-703	during	_
5-31	704-714	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-32	715-723	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-33	724-733	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-34	734-741	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-35	742-743	.	_

Text=We examined the relationship between imaging findings and clinical variables and performed mediation analyses to examine the inter-relationships between cue-related activations, tonic cocaine craving, and recent cocaine use.
6-1	744-746	We	_
6-2	747-755	examined	_
6-3	756-759	the	_
6-4	760-772	relationship	_
6-5	773-780	between	_
6-6	781-788	imaging	_
6-7	789-797	findings	_
6-8	798-801	and	_
6-9	802-810	clinical	_
6-10	811-820	variables	_
6-11	821-824	and	_
6-12	825-834	performed	_
6-13	835-844	mediation	_
6-14	845-853	analyses	_
6-15	854-856	to	_
6-16	857-864	examine	_
6-17	865-868	the	_
6-18	869-888	inter-relationships	_
6-19	889-896	between	_
6-20	897-908	cue-related	_
6-21	909-920	activations	_
6-22	921-922	,	_
6-23	923-928	tonic	_
6-24	929-936	cocaine	_
6-25	937-944	craving	_
6-26	945-946	,	_
6-27	947-950	and	_
6-28	951-957	recent	_
6-29	958-965	cocaine	_
6-30	966-969	use	_
6-31	970-971	.	_

Text=Results At a corrected threshold, cocaine-dependent participants demonstrated higher activation to cocaine than to food cues in the hypothalamus, inferior parietal cortex, and visual cortex.
7-1	972-979	Results	_
7-2	980-982	At	_
7-3	983-984	a	_
7-4	985-994	corrected	_
7-5	995-1004	threshold	_
7-6	1005-1006	,	_
7-7	1007-1024	cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
7-8	1025-1037	participants	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
7-9	1038-1050	demonstrated	_
7-10	1051-1057	higher	_
7-11	1058-1068	activation	_
7-12	1069-1071	to	_
7-13	1072-1079	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
7-14	1080-1084	than	_
7-15	1085-1087	to	_
7-16	1088-1092	food	_
7-17	1093-1097	cues	_
7-18	1098-1100	in	_
7-19	1101-1104	the	_
7-20	1105-1117	hypothalamus	_
7-21	1118-1119	,	_
7-22	1120-1128	inferior	_
7-23	1129-1137	parietal	_
7-24	1138-1144	cortex	_
7-25	1145-1146	,	_
7-26	1147-1150	and	_
7-27	1151-1157	visual	_
7-28	1158-1164	cortex	_
7-29	1165-1166	.	_

Text=Cocaine-dependent participants as compared with healthy control participants also demonstrated higher hypothalamic activation to food cues.
8-1	1167-1184	Cocaine-dependent	_
8-2	1185-1197	participants	_
8-3	1198-1200	as	_
8-4	1201-1209	compared	_
8-5	1210-1214	with	_
8-6	1215-1222	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-7	1223-1230	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-8	1231-1243	participants	_
8-9	1244-1248	also	_
8-10	1249-1261	demonstrated	_
8-11	1262-1268	higher	_
8-12	1269-1281	hypothalamic	_
8-13	1282-1292	activation	_
8-14	1293-1295	to	_
8-15	1296-1300	food	_
8-16	1301-1305	cues	_
8-17	1306-1307	.	_

Text=Further, the extent of these cue-induced hypothalamic activations was correlated with tonic craving, as assessed by the Cocaine Craving Questionnaire, and days of cocaine use in the prior month.
9-1	1308-1315	Further	_
9-2	1316-1317	,	_
9-3	1318-1321	the	_
9-4	1322-1328	extent	_
9-5	1329-1331	of	_
9-6	1332-1337	these	_
9-7	1338-1349	cue-induced	_
9-8	1350-1362	hypothalamic	_
9-9	1363-1374	activations	_
9-10	1375-1378	was	_
9-11	1379-1389	correlated	_
9-12	1390-1394	with	_
9-13	1395-1400	tonic	_
9-14	1401-1408	craving	_
9-15	1409-1410	,	_
9-16	1411-1413	as	_
9-17	1414-1422	assessed	_
9-18	1423-1425	by	_
9-19	1426-1429	the	_
9-20	1430-1437	Cocaine	_
9-21	1438-1445	Craving	_
9-22	1446-1459	Questionnaire	_
9-23	1460-1461	,	_
9-24	1462-1465	and	_
9-25	1466-1470	days	_
9-26	1471-1473	of	_
9-27	1474-1481	cocaine	_
9-28	1482-1485	use	_
9-29	1486-1488	in	_
9-30	1489-1492	the	_
9-31	1493-1498	prior	_
9-32	1499-1504	month	_
9-33	1505-1506	.	_

Text=In mediation analyses, hypothalamic activation to cocaine and food cues both completely mediated the relationship between the Cocaine Craving Questionnaire score and days of cocaine use in the past month.
10-1	1507-1509	In	_
10-2	1510-1519	mediation	_
10-3	1520-1528	analyses	_
10-4	1529-1530	,	_
10-5	1531-1543	hypothalamic	_
10-6	1544-1554	activation	_
10-7	1555-1557	to	_
10-8	1558-1565	cocaine	_
10-9	1566-1569	and	_
10-10	1570-1574	food	_
10-11	1575-1579	cues	_
10-12	1580-1584	both	_
10-13	1585-1595	completely	_
10-14	1596-1604	mediated	_
10-15	1605-1608	the	_
10-16	1609-1621	relationship	_
10-17	1622-1629	between	_
10-18	1630-1633	the	_
10-19	1634-1641	Cocaine	_
10-20	1642-1649	Craving	_
10-21	1650-1663	Questionnaire	_
10-22	1664-1669	score	_
10-23	1670-1673	and	_
10-24	1674-1678	days	_
10-25	1679-1681	of	_
10-26	1682-1689	cocaine	_
10-27	1690-1693	use	_
10-28	1694-1696	in	_
10-29	1697-1700	the	_
10-30	1701-1705	past	_
10-31	1706-1711	month	_
10-32	1712-1713	.	_

Text=Conclusions The results were consistent with the proposition that the mechanisms of feeding and drug addiction are inter-linked in the hypothalamus and altered in cocaine addiction.
11-1	1714-1725	Conclusions	_
11-2	1726-1729	The	_
11-3	1730-1737	results	_
11-4	1738-1742	were	_
11-5	1743-1753	consistent	_
11-6	1754-1758	with	_
11-7	1759-1762	the	_
11-8	1763-1774	proposition	_
11-9	1775-1779	that	_
11-10	1780-1783	the	_
11-11	1784-1794	mechanisms	_
11-12	1795-1797	of	_
11-13	1798-1805	feeding	_
11-14	1806-1809	and	_
11-15	1810-1814	drug	_
11-16	1815-1824	addiction	_
11-17	1825-1828	are	_
11-18	1829-1841	inter-linked	_
11-19	1842-1844	in	_
11-20	1845-1848	the	_
11-21	1849-1861	hypothalamus	_
11-22	1862-1865	and	_
11-23	1866-1873	altered	_
11-24	1874-1876	in	_
11-25	1877-1884	cocaine	_
11-26	1885-1894	addiction	_
11-27	1895-1896	.	_

Text=The findings provide new evidence in support of hypothalamic dysfunction in cocaine addiction.
12-1	1897-1900	The	_
12-2	1901-1909	findings	_
12-3	1910-1917	provide	_
12-4	1918-1921	new	_
12-5	1922-1930	evidence	_
12-6	1931-1933	in	_
12-7	1934-1941	support	_
12-8	1942-1944	of	_
12-9	1945-1957	hypothalamic	_
12-10	1958-1969	dysfunction	_
12-11	1970-1972	in	_
12-12	1973-1980	cocaine	_
12-13	1981-1990	addiction	_
12-14	1991-1992	.	_

Text=Materials and Methods Participants, Informed Consent, and Assessment Twenty recently abstinent participants with cocaine dependence (CD, 17 men) and 24 age-, gender-, and BMI-matched healthy controls (HC, 19 men) participated in the study (Table 1).
13-1	1993-2002	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-2	2003-2006	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-3	2007-2014	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-4	2015-2027	Participants	_
13-5	2028-2029	,	_
13-6	2030-2038	Informed	_
13-7	2039-2046	Consent	_
13-8	2047-2048	,	_
13-9	2049-2052	and	_
13-10	2053-2063	Assessment	_
13-11	2064-2070	Twenty	_
13-12	2071-2079	recently	_
13-13	2080-2089	abstinent	_
13-14	2090-2102	participants	_
13-15	2103-2107	with	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
13-16	2108-2115	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
13-17	2116-2126	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
13-18	2127-2128	(	_
13-19	2129-2131	CD	_
13-20	2132-2133	,	_
13-21	2134-2136	17	_
13-22	2137-2140	men	_
13-23	2141-2142	)	_
13-24	2143-2146	and	_
13-25	2147-2149	24	_
13-26	2150-2154	age-	_
13-27	2155-2156	,	_
13-28	2157-2164	gender-	_
13-29	2165-2166	,	_
13-30	2167-2170	and	_
13-31	2171-2182	BMI-matched	_
13-32	2183-2190	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-33	2191-2199	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-34	2200-2201	(	_
13-35	2202-2204	HC	_
13-36	2205-2206	,	_
13-37	2207-2209	19	_
13-38	2210-2213	men	_
13-39	2214-2215	)	_
13-40	2216-2228	participated	_
13-41	2229-2231	in	_
13-42	2232-2235	the	_
13-43	2236-2241	study	_
13-44	2242-2243	(	_
13-45	2244-2249	Table	_
13-46	2250-2251	1	_
13-47	2252-2253	)	_
13-48	2254-2255	.	_

Text=CD met criteria for current cocaine dependence as diagnosed by the Structured Clinical Interview for DSM-IV.
14-1	2256-2258	CD	_
14-2	2259-2262	met	_
14-3	2263-2271	criteria	_
14-4	2272-2275	for	_
14-5	2276-2283	current	_
14-6	2284-2291	cocaine	_
14-7	2292-2302	dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
14-8	2303-2305	as	_
14-9	2306-2315	diagnosed	_
14-10	2316-2318	by	_
14-11	2319-2322	the	_
14-12	2323-2333	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-13	2334-2342	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-14	2343-2352	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-15	2353-2356	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-16	2357-2363	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-17	2364-2365	.	_

Text=Recent cocaine use was confirmed by urine toxicology screens.
15-1	2366-2372	Recent	_
15-2	2373-2380	cocaine	_
15-3	2381-2384	use	_
15-4	2385-2388	was	_
15-5	2389-2398	confirmed	_
15-6	2399-2401	by	_
15-7	2402-2407	urine	_
15-8	2408-2418	toxicology	_
15-9	2419-2426	screens	_
15-10	2427-2428	.	_

Text=They were drug-free for about 7 to 10 days while staying in the Clinical Neuroscience Research Unit of the Connecticut Mental Health Center, a locked treatment facility, prior to the current fMRI study.
16-1	2429-2433	They	_
16-2	2434-2438	were	_
16-3	2439-2448	drug-free	_
16-4	2449-2452	for	_
16-5	2453-2458	about	_
16-6	2459-2460	7	_
16-7	2461-2463	to	_
16-8	2464-2466	10	_
16-9	2467-2471	days	_
16-10	2472-2477	while	_
16-11	2478-2485	staying	_
16-12	2486-2488	in	_
16-13	2489-2492	the	_
16-14	2493-2501	Clinical	_
16-15	2502-2514	Neuroscience	_
16-16	2515-2523	Research	_
16-17	2524-2528	Unit	_
16-18	2529-2531	of	_
16-19	2532-2535	the	_
16-20	2536-2547	Connecticut	_
16-21	2548-2554	Mental	_
16-22	2555-2561	Health	_
16-23	2562-2568	Center	_
16-24	2569-2570	,	_
16-25	2571-2572	a	_
16-26	2573-2579	locked	_
16-27	2580-2589	treatment	_
16-28	2590-2598	facility	_
16-29	2599-2600	,	_
16-30	2601-2606	prior	_
16-31	2607-2609	to	_
16-32	2610-2613	the	_
16-33	2614-2621	current	_
16-34	2622-2626	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
16-35	2627-2632	study	_
16-36	2633-2634	.	_

Text=All participants were physically healthy with no major medical illnesses or current use of prescription medications.
17-1	2635-2638	All	_
17-2	2639-2651	participants	_
17-3	2652-2656	were	_
17-4	2657-2667	physically	_
17-5	2668-2675	healthy	_
17-6	2676-2680	with	_
17-7	2681-2683	no	_
17-8	2684-2689	major	_
17-9	2690-2697	medical	_
17-10	2698-2707	illnesses	_
17-11	2708-2710	or	_
17-12	2711-2718	current	_
17-13	2719-2722	use	_
17-14	2723-2725	of	_
17-15	2726-2738	prescription	_
17-16	2739-2750	medications	_
17-17	2751-2752	.	_

Text=None reported having a history of head injury or neurological illness.
18-1	2753-2757	None	_
18-2	2758-2766	reported	_
18-3	2767-2773	having	_
18-4	2774-2775	a	_
18-5	2776-2783	history	_
18-6	2784-2786	of	_
18-7	2787-2791	head	_
18-8	2792-2798	injury	_
18-9	2799-2801	or	_
18-10	2802-2814	neurological	_
18-11	2815-2822	illness	_
18-12	2823-2824	.	_

Text=Other exclusion criteria included dependence on another psychoactive substance (except nicotine) and current or past history of Axis I disorders.
19-1	2825-2830	Other	_
19-2	2831-2840	exclusion	_
19-3	2841-2849	criteria	_
19-4	2850-2858	included	_
19-5	2859-2869	dependence	_
19-6	2870-2872	on	_
19-7	2873-2880	another	_
19-8	2881-2893	psychoactive	_
19-9	2894-2903	substance	_
19-10	2904-2905	(	_
19-11	2906-2912	except	_
19-12	2913-2921	nicotine	_
19-13	2922-2923	)	_
19-14	2924-2927	and	_
19-15	2928-2935	current	_
19-16	2936-2938	or	_
19-17	2939-2943	past	_
19-18	2944-2951	history	_
19-19	2952-2954	of	_
19-20	2955-2959	Axis	_
19-21	2960-2961	I	_
19-22	2962-2971	disorders	_
19-23	2972-2973	.	_

Text=The Human Investigation Committee at Yale University School of Medicine approved the study procedures, and all participants signed an informed consent prior to the study.
20-1	2974-2977	The	_
20-2	2978-2983	Human	_
20-3	2984-2997	Investigation	_
20-4	2998-3007	Committee	_
20-5	3008-3010	at	_
20-6	3011-3015	Yale	_
20-7	3016-3026	University	_
20-8	3027-3033	School	_
20-9	3034-3036	of	_
20-10	3037-3045	Medicine	_
20-11	3046-3054	approved	_
20-12	3055-3058	the	_
20-13	3059-3064	study	_
20-14	3065-3075	procedures	_
20-15	3076-3077	,	_
20-16	3078-3081	and	_
20-17	3082-3085	all	_
20-18	3086-3098	participants	_
20-19	3099-3105	signed	_
20-20	3106-3108	an	_
20-21	3109-3117	informed	_
20-22	3118-3125	consent	_
20-23	3126-3131	prior	_
20-24	3132-3134	to	_
20-25	3135-3138	the	_
20-26	3139-3144	study	_
20-27	3145-3146	.	_

Text=CD participants were interviewed with the 18-item CSSA to evaluate cocaine withdrawal signs and symptoms.
21-1	3147-3149	CD	_
21-2	3150-3162	participants	_
21-3	3163-3167	were	_
21-4	3168-3179	interviewed	_
21-5	3180-3184	with	_
21-6	3185-3188	the	_
21-7	3189-3196	18-item	_
21-8	3197-3201	CSSA	_
21-9	3202-3204	to	_
21-10	3205-3213	evaluate	_
21-11	3214-3221	cocaine	_
21-12	3222-3232	withdrawal	_
21-13	3233-3238	signs	_
21-14	3239-3242	and	_
21-15	3243-3251	symptoms	_
21-16	3252-3253	.	_

Text=CSSA scores were highly correlated with recent cocaine use and with severity measures of the Addiction Severity Index, including the interviewer severity rating and composite score in the drug section.
22-1	3254-3258	CSSA	http://maven.renci.org/NeuroBridge/neurobridge#dimerAssay
22-2	3259-3265	scores	_
22-3	3266-3270	were	_
22-4	3271-3277	highly	_
22-5	3278-3288	correlated	_
22-6	3289-3293	with	_
22-7	3294-3300	recent	_
22-8	3301-3308	cocaine	_
22-9	3309-3312	use	_
22-10	3313-3316	and	_
22-11	3317-3321	with	_
22-12	3322-3330	severity	_
22-13	3331-3339	measures	_
22-14	3340-3342	of	_
22-15	3343-3346	the	_
22-16	3347-3356	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
22-17	3357-3365	Severity	_
22-18	3366-3371	Index	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
22-19	3372-3373	,	_
22-20	3374-3383	including	_
22-21	3384-3387	the	_
22-22	3388-3399	interviewer	_
22-23	3400-3408	severity	_
22-24	3409-3415	rating	_
22-25	3416-3419	and	_
22-26	3420-3429	composite	_
22-27	3430-3435	score	_
22-28	3436-3438	in	_
22-29	3439-3442	the	_
22-30	3443-3447	drug	_
22-31	3448-3455	section	_
22-32	3456-3457	.	_

Text=For cocaine-dependent individuals, initial CSSA scores were higher for those who failed to achieve abstinence or who subsequently dropped out of treatment.
23-1	3458-3461	For	_
23-2	3462-3479	cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
23-3	3480-3491	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
23-4	3492-3493	,	_
23-5	3494-3501	initial	_
23-6	3502-3506	CSSA	_
23-7	3507-3513	scores	_
23-8	3514-3518	were	_
23-9	3519-3525	higher	_
23-10	3526-3529	for	_
23-11	3530-3535	those	_
23-12	3536-3539	who	_
23-13	3540-3546	failed	_
23-14	3547-3549	to	_
23-15	3550-3557	achieve	_
23-16	3558-3568	abstinence	_
23-17	3569-3571	or	_
23-18	3572-3575	who	_
23-19	3576-3588	subsequently	_
23-20	3589-3596	dropped	_
23-21	3597-3600	out	_
23-22	3601-3603	of	_
23-23	3604-3613	treatment	_
23-24	3614-3615	.	_

Text=Cocaine craving was assessed with the Cocaine Craving Questionnaire-Brief version for all CDs every 2 to 3 days.
24-1	3616-3623	Cocaine	_
24-2	3624-3631	craving	_
24-3	3632-3635	was	_
24-4	3636-3644	assessed	_
24-5	3645-3649	with	_
24-6	3650-3653	the	_
24-7	3654-3661	Cocaine	_
24-8	3662-3669	Craving	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
24-9	3670-3689	Questionnaire-Brief	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
24-10	3690-3697	version	_
24-11	3698-3701	for	_
24-12	3702-3705	all	_
24-13	3706-3709	CDs	_
24-14	3710-3715	every	_
24-15	3716-3717	2	_
24-16	3718-3720	to	_
24-17	3721-3722	3	_
24-18	3723-3727	days	_
24-19	3728-3729	.	_

Text=The CCQ-Brief version is a 10-item questionnaire abbreviated from the CCQ-Now and highly congruent with the CCQ-Now and other cocaine craving measures.
25-1	3730-3733	The	_
25-2	3734-3743	CCQ-Brief	_
25-3	3744-3751	version	_
25-4	3752-3754	is	_
25-5	3755-3756	a	_
25-6	3757-3764	10-item	_
25-7	3765-3778	questionnaire	_
25-8	3779-3790	abbreviated	_
25-9	3791-3795	from	_
25-10	3796-3799	the	_
25-11	3800-3807	CCQ-Now	_
25-12	3808-3811	and	_
25-13	3812-3818	highly	_
25-14	3819-3828	congruent	_
25-15	3829-3833	with	_
25-16	3834-3837	the	_
25-17	3838-3845	CCQ-Now	_
25-18	3846-3849	and	_
25-19	3850-3855	other	_
25-20	3856-3863	cocaine	_
25-21	3864-3871	craving	_
25-22	3872-3880	measures	_
25-23	3881-3882	.	_

Text=Each item was rated on a scale from 1 to 7, with a higher total score (ranging from 10 to 70) indicating greater craving.
26-1	3883-3887	Each	_
26-2	3888-3892	item	_
26-3	3893-3896	was	_
26-4	3897-3902	rated	_
26-5	3903-3905	on	_
26-6	3906-3907	a	_
26-7	3908-3913	scale	_
26-8	3914-3918	from	_
26-9	3919-3920	1	_
26-10	3921-3923	to	_
26-11	3924-3925	7	_
26-12	3926-3927	,	_
26-13	3928-3932	with	_
26-14	3933-3934	a	_
26-15	3935-3941	higher	_
26-16	3942-3947	total	_
26-17	3948-3953	score	_
26-18	3954-3955	(	_
26-19	3956-3963	ranging	_
26-20	3964-3968	from	_
26-21	3969-3971	10	_
26-22	3972-3974	to	_
26-23	3975-3977	70	_
26-24	3978-3979	)	_
26-25	3980-3990	indicating	_
26-26	3991-3998	greater	_
26-27	3999-4006	craving	_
26-28	4007-4008	.	_

Text=CCQ score was averaged across all assessments during the 2- to 3-week inpatient stay to index a tonic level of craving.
27-1	4009-4012	CCQ	_
27-2	4013-4018	score	_
27-3	4019-4022	was	_
27-4	4023-4031	averaged	_
27-5	4032-4038	across	_
27-6	4039-4042	all	_
27-7	4043-4054	assessments	_
27-8	4055-4061	during	_
27-9	4062-4065	the	_
27-10	4066-4068	2-	_
27-11	4069-4071	to	_
27-12	4072-4078	3-week	_
27-13	4079-4088	inpatient	_
27-14	4089-4093	stay	_
27-15	4094-4096	to	_
27-16	4097-4102	index	_
27-17	4103-4104	a	_
27-18	4105-4110	tonic	_
27-19	4111-4116	level	_
27-20	4117-4119	of	_
27-21	4120-4127	craving	_
27-22	4128-4129	.	_

Text=Behavioral Tasks We employed a cue-induced cocaine craving task (CCT) for CD only and a cue-induced food craving task (FCT) for both CD and HC (Figure 1).
28-1	4130-4140	Behavioral	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
28-2	4141-4146	Tasks	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
28-3	4147-4149	We	_
28-4	4150-4158	employed	_
28-5	4159-4160	a	_
28-6	4161-4172	cue-induced	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
28-7	4173-4180	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
28-8	4181-4188	craving	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
28-9	4189-4193	task	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
28-10	4194-4195	(	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
28-11	4196-4199	CCT	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
28-12	4200-4201	)	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
28-13	4202-4205	for	_
28-14	4206-4208	CD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
28-15	4209-4213	only	_
28-16	4214-4217	and	_
28-17	4218-4219	a	_
28-18	4220-4231	cue-induced	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-19	4232-4236	food	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-20	4237-4244	craving	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-21	4245-4249	task	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-22	4250-4251	(	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-23	4252-4255	FCT	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-24	4256-4257	)	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-25	4258-4261	for	_
28-26	4262-4266	both	_
28-27	4267-4269	CD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
28-28	4270-4273	and	_
28-29	4274-4276	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
28-30	4277-4278	(	_
28-31	4279-4285	Figure	_
28-32	4286-4287	1	_
28-33	4288-4289	)	_
28-34	4290-4291	.	_

Text=The order of CCT and FCT was counter-balanced across subjects for CD.
29-1	4292-4295	The	_
29-2	4296-4301	order	_
29-3	4302-4304	of	_
29-4	4305-4308	CCT	_
29-5	4309-4312	and	_
29-6	4313-4316	FCT	_
29-7	4317-4320	was	_
29-8	4321-4337	counter-balanced	_
29-9	4338-4344	across	_
29-10	4345-4353	subjects	_
29-11	4354-4357	for	_
29-12	4358-4360	CD	_
29-13	4361-4362	.	_

Text=Details can be found in the Supplement.
30-1	4363-4370	Details	_
30-2	4371-4374	can	_
30-3	4375-4377	be	_
30-4	4378-4383	found	_
30-5	4384-4386	in	_
30-6	4387-4390	the	_
30-7	4391-4401	Supplement	_
30-8	4402-4403	.	_

Text=Imaging Protocol and Data Preprocessing The imaging protocol is described in detail in the Supplement.
31-1	4404-4411	Imaging	_
31-2	4412-4420	Protocol	_
31-3	4421-4424	and	_
31-4	4425-4429	Data	_
31-5	4430-4443	Preprocessing	_
31-6	4444-4447	The	_
31-7	4448-4455	imaging	_
31-8	4456-4464	protocol	_
31-9	4465-4467	is	_
31-10	4468-4477	described	_
31-11	4478-4480	in	_
31-12	4481-4487	detail	_
31-13	4488-4490	in	_
31-14	4491-4494	the	_
31-15	4495-4505	Supplement	_
31-16	4506-4507	.	_

Text=Data were analyzed with SPM (Statistical Parametric Mapping) software following established routines, as in the Supplement.
32-1	4508-4512	Data	_
32-2	4513-4517	were	_
32-3	4518-4526	analyzed	_
32-4	4527-4531	with	_
32-5	4532-4535	SPM	_
32-6	4536-4537	(	_
32-7	4538-4549	Statistical	_
32-8	4550-4560	Parametric	_
32-9	4561-4568	Mapping	_
32-10	4569-4570	)	_
32-11	4571-4579	software	_
32-12	4580-4589	following	_
32-13	4590-4601	established	_
32-14	4602-4610	routines	_
32-15	4611-4612	,	_
32-16	4613-4615	as	_
32-17	4616-4618	in	_
32-18	4619-4622	the	_
32-19	4623-4633	Supplement	_
32-20	4634-4635	.	_

Text=Imaging Data Modeling Data blocks were first distinguished by “ cocaine/food picture ” and “ neutral picture ” for CCT/FCT.
33-1	4636-4643	Imaging	_
33-2	4644-4648	Data	_
33-3	4649-4657	Modeling	_
33-4	4658-4662	Data	_
33-5	4663-4669	blocks	_
33-6	4670-4674	were	_
33-7	4675-4680	first	_
33-8	4681-4694	distinguished	_
33-9	4695-4697	by	_
33-10	4698-4699	“	_
33-11	4700-4712	cocaine/food	_
33-12	4713-4720	picture	_
33-13	4721-4722	”	_
33-14	4723-4726	and	_
33-15	4727-4728	“	_
33-16	4729-4736	neutral	_
33-17	4737-4744	picture	_
33-18	4745-4746	”	_
33-19	4747-4750	for	_
33-20	4751-4758	CCT/FCT	_
33-21	4759-4760	.	_

Text=A statistical analytical block design was constructed for each participant using a general linear model.
34-1	4761-4762	A	_
34-2	4763-4774	statistical	_
34-3	4775-4785	analytical	_
34-4	4786-4791	block	_
34-5	4792-4798	design	_
34-6	4799-4802	was	_
34-7	4803-4814	constructed	_
34-8	4815-4818	for	_
34-9	4819-4823	each	_
34-10	4824-4835	participant	_
34-11	4836-4841	using	_
34-12	4842-4843	a	_
34-13	4844-4851	general	_
34-14	4852-4858	linear	_
34-15	4859-4864	model	_
34-16	4865-4866	.	_

Text=Because each block was associated with a craving rating, we included a column of block onset parametrically modulated by its corresponding craving score as a regressor in the model.
35-1	4867-4874	Because	_
35-2	4875-4879	each	_
35-3	4880-4885	block	_
35-4	4886-4889	was	_
35-5	4890-4900	associated	_
35-6	4901-4905	with	_
35-7	4906-4907	a	_
35-8	4908-4915	craving	_
35-9	4916-4922	rating	_
35-10	4923-4924	,	_
35-11	4925-4927	we	_
35-12	4928-4936	included	_
35-13	4937-4938	a	_
35-14	4939-4945	column	_
35-15	4946-4948	of	_
35-16	4949-4954	block	_
35-17	4955-4960	onset	_
35-18	4961-4975	parametrically	_
35-19	4976-4985	modulated	_
35-20	4986-4988	by	_
35-21	4989-4992	its	_
35-22	4993-5006	corresponding	_
35-23	5007-5014	craving	_
35-24	5015-5020	score	_
35-25	5021-5023	as	_
35-26	5024-5025	a	_
35-27	5026-5035	regressor	_
35-28	5036-5038	in	_
35-29	5039-5042	the	_
35-30	5043-5048	model	_
35-31	5049-5050	.	_

Text=Realignment parameters in all 6 dimensions were also entered in the model.
36-1	5051-5062	Realignment	_
36-2	5063-5073	parameters	_
36-3	5074-5076	in	_
36-4	5077-5080	all	_
36-5	5081-5082	6	_
36-6	5083-5093	dimensions	_
36-7	5094-5098	were	_
36-8	5099-5103	also	_
36-9	5104-5111	entered	_
36-10	5112-5114	in	_
36-11	5115-5118	the	_
36-12	5119-5124	model	_
36-13	5125-5126	.	_

Text=Serial autocorrelation caused by aliased cardiovascular and respiratory effects was corrected by a first-degree autoregressive or AR (1) model.
37-1	5127-5133	Serial	_
37-2	5134-5149	autocorrelation	_
37-3	5150-5156	caused	_
37-4	5157-5159	by	_
37-5	5160-5167	aliased	_
37-6	5168-5182	cardiovascular	_
37-7	5183-5186	and	_
37-8	5187-5198	respiratory	_
37-9	5199-5206	effects	_
37-10	5207-5210	was	_
37-11	5211-5220	corrected	_
37-12	5221-5223	by	_
37-13	5224-5225	a	_
37-14	5226-5238	first-degree	_
37-15	5239-5253	autoregressive	_
37-16	5254-5256	or	_
37-17	5257-5259	AR	_
37-18	5260-5261	(	_
37-19	5262-5263	1	_
37-20	5264-5265	)	_
37-21	5266-5271	model	_
37-22	5272-5273	.	_

Text=The general linear model estimated the component of variance that could be explained by each of the regressors.
38-1	5274-5277	The	_
38-2	5278-5285	general	_
38-3	5286-5292	linear	_
38-4	5293-5298	model	_
38-5	5299-5308	estimated	_
38-6	5309-5312	the	_
38-7	5313-5322	component	_
38-8	5323-5325	of	_
38-9	5326-5334	variance	_
38-10	5335-5339	that	_
38-11	5340-5345	could	_
38-12	5346-5348	be	_
38-13	5349-5358	explained	_
38-14	5359-5361	by	_
38-15	5362-5366	each	_
38-16	5367-5369	of	_
38-17	5370-5373	the	_
38-18	5374-5384	regressors	_
38-19	5385-5386	.	_

Text=In the first-level analysis, we constructed for each participant statistical contrasts of “ cocaine picture ” vs “ neutral picture ” for CCT and “ food picture ” vs “ neutral picture ” for FCT.
39-1	5387-5389	In	_
39-2	5390-5393	the	_
39-3	5394-5405	first-level	_
39-4	5406-5414	analysis	_
39-5	5415-5416	,	_
39-6	5417-5419	we	_
39-7	5420-5431	constructed	_
39-8	5432-5435	for	_
39-9	5436-5440	each	_
39-10	5441-5452	participant	_
39-11	5453-5464	statistical	_
39-12	5465-5474	contrasts	_
39-13	5475-5477	of	_
39-14	5478-5479	“	_
39-15	5480-5487	cocaine	_
39-16	5488-5495	picture	_
39-17	5496-5497	”	_
39-18	5498-5500	vs	_
39-19	5501-5502	“	_
39-20	5503-5510	neutral	_
39-21	5511-5518	picture	_
39-22	5519-5520	”	_
39-23	5521-5524	for	_
39-24	5525-5528	CCT	_
39-25	5529-5532	and	_
39-26	5533-5534	“	_
39-27	5535-5539	food	_
39-28	5540-5547	picture	_
39-29	5548-5549	”	_
39-30	5550-5552	vs	_
39-31	5553-5554	“	_
39-32	5555-5562	neutral	_
39-33	5563-5570	picture	_
39-34	5571-5572	”	_
39-35	5573-5576	for	_
39-36	5577-5580	FCT	_
39-37	5581-5582	.	_

Text=These contrasts allowed us to evaluate brain regions that responded differently to viewing of cocaine and food pictures, compared with viewing of neutral pictures, in CCT and FCT, respectively.
40-1	5583-5588	These	_
40-2	5589-5598	contrasts	_
40-3	5599-5606	allowed	_
40-4	5607-5609	us	_
40-5	5610-5612	to	_
40-6	5613-5621	evaluate	_
40-7	5622-5627	brain	_
40-8	5628-5635	regions	_
40-9	5636-5640	that	_
40-10	5641-5650	responded	_
40-11	5651-5662	differently	_
40-12	5663-5665	to	_
40-13	5666-5673	viewing	_
40-14	5674-5676	of	_
40-15	5677-5684	cocaine	_
40-16	5685-5688	and	_
40-17	5689-5693	food	_
40-18	5694-5702	pictures	_
40-19	5703-5704	,	_
40-20	5705-5713	compared	_
40-21	5714-5718	with	_
40-22	5719-5726	viewing	_
40-23	5727-5729	of	_
40-24	5730-5737	neutral	_
40-25	5738-5746	pictures	_
40-26	5747-5748	,	_
40-27	5749-5751	in	_
40-28	5752-5755	CCT	_
40-29	5756-5759	and	_
40-30	5760-5763	FCT	_
40-31	5764-5765	,	_
40-32	5766-5778	respectively	_
40-33	5779-5780	.	_

Text=The contrast images of the first-level analysis were then used for the second-level group statistics.
41-1	5781-5784	The	_
41-2	5785-5793	contrast	_
41-3	5794-5800	images	_
41-4	5801-5803	of	_
41-5	5804-5807	the	_
41-6	5808-5819	first-level	_
41-7	5820-5828	analysis	_
41-8	5829-5833	were	_
41-9	5834-5838	then	_
41-10	5839-5843	used	_
41-11	5844-5847	for	_
41-12	5848-5851	the	_
41-13	5852-5864	second-level	_
41-14	5865-5870	group	_
41-15	5871-5881	statistics	_
41-16	5882-5883	.	_

Text=We conducted paired t test to examine differences between “ cocaine picture ” vs “ neutral picture ” and “ food picture ” vs “ neutral picture ” in CD and 2-sample t test to examine differences between CD and HC for contrast of “ food picture ” vs “ neutral picture. ” In addition to whole-brain analyses, we examined cue-related responses of the hypothalamus with a mask as in earlier studies.
42-1	5884-5886	We	_
42-2	5887-5896	conducted	_
42-3	5897-5903	paired	_
42-4	5904-5905	t	_
42-5	5906-5910	test	_
42-6	5911-5913	to	_
42-7	5914-5921	examine	_
42-8	5922-5933	differences	_
42-9	5934-5941	between	_
42-10	5942-5943	“	_
42-11	5944-5951	cocaine	_
42-12	5952-5959	picture	_
42-13	5960-5961	”	_
42-14	5962-5964	vs	_
42-15	5965-5966	“	_
42-16	5967-5974	neutral	_
42-17	5975-5982	picture	_
42-18	5983-5984	”	_
42-19	5985-5988	and	_
42-20	5989-5990	“	_
42-21	5991-5995	food	_
42-22	5996-6003	picture	_
42-23	6004-6005	”	_
42-24	6006-6008	vs	_
42-25	6009-6010	“	_
42-26	6011-6018	neutral	_
42-27	6019-6026	picture	_
42-28	6027-6028	”	_
42-29	6029-6031	in	_
42-30	6032-6034	CD	_
42-31	6035-6038	and	_
42-32	6039-6047	2-sample	_
42-33	6048-6049	t	_
42-34	6050-6054	test	_
42-35	6055-6057	to	_
42-36	6058-6065	examine	_
42-37	6066-6077	differences	_
42-38	6078-6085	between	_
42-39	6086-6088	CD	_
42-40	6089-6092	and	_
42-41	6093-6095	HC	_
42-42	6096-6099	for	_
42-43	6100-6108	contrast	_
42-44	6109-6111	of	_
42-45	6112-6113	“	_
42-46	6114-6118	food	_
42-47	6119-6126	picture	_
42-48	6127-6128	”	_
42-49	6129-6131	vs	_
42-50	6132-6133	“	_
42-51	6134-6141	neutral	_
42-52	6142-6150	picture.	_
42-53	6151-6152	”	_
42-54	6153-6155	In	_
42-55	6156-6164	addition	_
42-56	6165-6167	to	_
42-57	6168-6179	whole-brain	_
42-58	6180-6188	analyses	_
42-59	6189-6190	,	_
42-60	6191-6193	we	_
42-61	6194-6202	examined	_
42-62	6203-6214	cue-related	_
42-63	6215-6224	responses	_
42-64	6225-6227	of	_
42-65	6228-6231	the	_
42-66	6232-6244	hypothalamus	_
42-67	6245-6249	with	_
42-68	6250-6251	a	_
42-69	6252-6256	mask	_
42-70	6257-6259	as	_
42-71	6260-6262	in	_
42-72	6263-6270	earlier	_
42-73	6271-6278	studies	_
42-74	6279-6280	.	_

Text=Following current reporting standards, all imaging results were evaluated with voxel P <.001, uncorrected, in combination with cluster P <.05, FWE or family-wise error corrected for the whole brain or small volume correction for a hypothalamus mask obtained from the WFU Pick Atlas (http: //fmri.wfubmc.edu/software/pickatlas), on the basis of Gaussian random field theory as implemented in SPM.
43-1	6281-6290	Following	_
43-2	6291-6298	current	_
43-3	6299-6308	reporting	_
43-4	6309-6318	standards	_
43-5	6319-6320	,	_
43-6	6321-6324	all	_
43-7	6325-6332	imaging	_
43-8	6333-6340	results	_
43-9	6341-6345	were	_
43-10	6346-6355	evaluated	_
43-11	6356-6360	with	_
43-12	6361-6366	voxel	_
43-13	6367-6368	P	_
43-14	6369-6370	<	_
43-15	6371-6375	.001	_
43-16	6376-6377	,	_
43-17	6378-6389	uncorrected	_
43-18	6390-6391	,	_
43-19	6392-6394	in	_
43-20	6395-6406	combination	_
43-21	6407-6411	with	_
43-22	6412-6419	cluster	_
43-23	6420-6421	P	_
43-24	6422-6423	<	_
43-25	6424-6427	.05	_
43-26	6428-6429	,	_
43-27	6430-6433	FWE	_
43-28	6434-6436	or	_
43-29	6437-6448	family-wise	_
43-30	6449-6454	error	_
43-31	6455-6464	corrected	_
43-32	6465-6468	for	_
43-33	6469-6472	the	_
43-34	6473-6478	whole	_
43-35	6479-6484	brain	_
43-36	6485-6487	or	_
43-37	6488-6493	small	_
43-38	6494-6500	volume	_
43-39	6501-6511	correction	_
43-40	6512-6515	for	_
43-41	6516-6517	a	_
43-42	6518-6530	hypothalamus	_
43-43	6531-6535	mask	_
43-44	6536-6544	obtained	_
43-45	6545-6549	from	_
43-46	6550-6553	the	_
43-47	6554-6557	WFU	_
43-48	6558-6562	Pick	_
43-49	6563-6568	Atlas	_
43-50	6569-6570	(	_
43-51	6571-6575	http	_
43-52	6576-6577	:	_
43-53	6578-6614	//fmri.wfubmc.edu/software/pickatlas	_
43-54	6615-6616	)	_
43-55	6617-6618	,	_
43-56	6619-6621	on	_
43-57	6622-6625	the	_
43-58	6626-6631	basis	_
43-59	6632-6634	of	_
43-60	6635-6643	Gaussian	_
43-61	6644-6650	random	_
43-62	6651-6656	field	_
43-63	6657-6663	theory	_
43-64	6664-6666	as	_
43-65	6667-6678	implemented	_
43-66	6679-6681	in	_
43-67	6682-6685	SPM	_
43-68	6686-6687	.	_

Text=With small volume correction, one applied standard voxel level statistics (e.g., FWE) to voxels within the small region instead of within the whole brain.
44-1	6688-6692	With	_
44-2	6693-6698	small	_
44-3	6699-6705	volume	_
44-4	6706-6716	correction	_
44-5	6717-6718	,	_
44-6	6719-6722	one	_
44-7	6723-6730	applied	_
44-8	6731-6739	standard	_
44-9	6740-6745	voxel	_
44-10	6746-6751	level	_
44-11	6752-6762	statistics	_
44-12	6763-6764	(	_
44-13	6765-6769	e.g.	_
44-14	6770-6771	,	_
44-15	6772-6775	FWE	_
44-16	6776-6777	)	_
44-17	6778-6780	to	_
44-18	6781-6787	voxels	_
44-19	6788-6794	within	_
44-20	6795-6798	the	_
44-21	6799-6804	small	_
44-22	6805-6811	region	_
44-23	6812-6819	instead	_
44-24	6820-6822	of	_
44-25	6823-6829	within	_
44-26	6830-6833	the	_
44-27	6834-6839	whole	_
44-28	6840-6845	brain	_
44-29	6846-6847	.	_

Text=On the basis of our previous study, we had a very strong hypothesis that the hypothalamus would show differences in cue-related activities in the study.
45-1	6848-6850	On	_
45-2	6851-6854	the	_
45-3	6855-6860	basis	_
45-4	6861-6863	of	_
45-5	6864-6867	our	_
45-6	6868-6876	previous	_
45-7	6877-6882	study	_
45-8	6883-6884	,	_
45-9	6885-6887	we	_
45-10	6888-6891	had	_
45-11	6892-6893	a	_
45-12	6894-6898	very	_
45-13	6899-6905	strong	_
45-14	6906-6916	hypothesis	_
45-15	6917-6921	that	_
45-16	6922-6925	the	_
45-17	6926-6938	hypothalamus	_
45-18	6939-6944	would	_
45-19	6945-6949	show	_
45-20	6950-6961	differences	_
45-21	6962-6964	in	_
45-22	6965-6976	cue-related	_
45-23	6977-6987	activities	_
45-24	6988-6990	in	_
45-25	6991-6994	the	_
45-26	6995-7000	study	_
45-27	7001-7002	.	_

Text=Thus, we tested the hypothesis using small volume correction.
46-1	7003-7007	Thus	_
46-2	7008-7009	,	_
46-3	7010-7012	we	_
46-4	7013-7019	tested	_
46-5	7020-7023	the	_
46-6	7024-7034	hypothesis	_
46-7	7035-7040	using	_
46-8	7041-7046	small	_
46-9	7047-7053	volume	_
46-10	7054-7064	correction	_
46-11	7065-7066	.	_

Text=In region of interest (ROI) analysis, we used MarsBaR (http: //marsbar.sourceforge.net/) to derive for each participant the activity difference (β contrast) for the ROIs.
47-1	7067-7069	In	_
47-2	7070-7076	region	_
47-3	7077-7079	of	_
47-4	7080-7088	interest	_
47-5	7089-7090	(	_
47-6	7091-7094	ROI	_
47-7	7095-7096	)	_
47-8	7097-7105	analysis	_
47-9	7106-7107	,	_
47-10	7108-7110	we	_
47-11	7111-7115	used	_
47-12	7116-7123	MarsBaR	_
47-13	7124-7125	(	_
47-14	7126-7130	http	_
47-15	7131-7132	:	_
47-16	7133-7159	//marsbar.sourceforge.net/	_
47-17	7160-7161	)	_
47-18	7162-7164	to	_
47-19	7165-7171	derive	_
47-20	7172-7175	for	_
47-21	7176-7180	each	_
47-22	7181-7192	participant	_
47-23	7193-7196	the	_
47-24	7197-7205	activity	_
47-25	7206-7216	difference	_
47-26	7217-7218	(	_
47-27	7219-7220	β	_
47-28	7221-7229	contrast	_
47-29	7230-7231	)	_
47-30	7232-7235	for	_
47-31	7236-7239	the	_
47-32	7240-7244	ROIs	_
47-33	7245-7246	.	_

Text=Functional ROIs were defined based on clusters obtained from whole brain analysis.
48-1	7247-7257	Functional	_
48-2	7258-7262	ROIs	_
48-3	7263-7267	were	_
48-4	7268-7275	defined	_
48-5	7276-7281	based	_
48-6	7282-7284	on	_
48-7	7285-7293	clusters	_
48-8	7294-7302	obtained	_
48-9	7303-7307	from	_
48-10	7308-7313	whole	_
48-11	7314-7319	brain	_
48-12	7320-7328	analysis	_
48-13	7329-7330	.	_

Text=All voxel activations were presented in Montreal Neurological Institute coordinates.
49-1	7331-7334	All	_
49-2	7335-7340	voxel	_
49-3	7341-7352	activations	_
49-4	7353-7357	were	_
49-5	7358-7367	presented	_
49-6	7368-7370	in	_
49-7	7371-7379	Montreal	_
49-8	7380-7392	Neurological	_
49-9	7393-7402	Institute	_
49-10	7403-7414	coordinates	_
49-11	7415-7416	.	_

Text=Mediation Analysis Owing to space limitations, mediation analyses are presented in the Supplement.
50-1	7417-7426	Mediation	_
50-2	7427-7435	Analysis	_
50-3	7436-7441	Owing	_
50-4	7442-7444	to	_
50-5	7445-7450	space	_
50-6	7451-7462	limitations	_
50-7	7463-7464	,	_
50-8	7465-7474	mediation	_
50-9	7475-7483	analyses	_
50-10	7484-7487	are	_
50-11	7488-7497	presented	_
50-12	7498-7500	in	_
50-13	7501-7504	the	_
50-14	7505-7515	Supplement	_
50-15	7516-7517	.	_

